Biotech News

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

Viking Therapeutics (VKTX)Viking Therapeutics2026-05-12 11:05 ESTClinical readout

VKTX (VKTX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vktx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VKTXViking Therapeutics2026-03-26 11:05 EST

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

ALGSAligos Therapeutics2026-05-27 06:30 EST

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

MLYSMineralys Therapeutics2026-05-18 20:05 EST

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

CRNXCrinetics Pharmaceuticals2026-06-14 20:30 EST

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

CORTCorcept2026-04-10 20:45 EST

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-03-28 18:45 EST

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

ALGSAligos Therapeutics2026-01-21 13:00 EST

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

View all latest news

Viking Therapeutics

Viking Therapeutics is a metabolic-disease biotech focused on obesity and related cardiometabolic opportunities.

Recent company news

VKTXViking Therapeutics2026-07-23 11:05 EST

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

VKTXViking Therapeutics2026-05-21 11:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

Stock data

Close: 34.87 USD
Market cap: 3.4B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States